Cancer therapy is once again experiencing a paradigm shift. This shift is based on extensive clinical experience demonstrating that cancer cannot be successfully fought by addressing only single targets or pathways. Even the combination of several neo-antigens in cancer vaccines is not sufficient for successful, lasting tumor eradication. The focus has therefore shifted to the immune system's role in cancer and the striking abilities of cancer cells to manipulate and/or deactivate the immune system. Researchers and pharma companies have started to target the processes and cells known to support immune surveillance and the elimination of tumor cells. Immune processes, however, require novel concepts beyond the traditional “single-target–single drug” paradigm and need parallel targeting of diverse cells and mechanisms. This review gives a perspective on the role of gene therapy technologies in the evolving immuno-oncology space and identifies gene therapy as a major driver in the development and regulation of effective cancer immunotherapy. Present challenges and breakthroughs ranging from chimeric antigen receptor T-cell therapy, gene-modified oncolytic viruses, combination cancer vaccines, to RNA therapeutics are spotlighted. Gene therapy is recognized as the most prominent technology enabling effective immuno-oncology strategies.
Get full access to this article
View all access options for this article.
References
1.
AlexanderW. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T, 2016; 41:185–191.
2.
FoxBA, SchendelDJ, ButterfieldLH, et al.Defining the critical hurdles in cancer immunotherapy. J Transl Med, 2011; 9:214.
3.
MarkabiS. Combination therapy from the regulatory perspective. Retina, 2009; 29:S12–S14.
4.
PerryD, SperlingR, KatzR, et al.Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother, 2015; 15:327–333.
5.
KaufmannKB, BüningH, GalyA, et al.Gene therapy on the move. EMBO Mol Med, 2013; 5:1642–1661.
6.
PaluckaK, BanchereauJ. Dendritic-cell-based therapeutic cancer vaccines. Immunity, 2013; 39:38–48.
7.
ChenS, SunH, MiaoK, et al.CRISPR-Cas9: from genome editing to cancer research. Int J Biol Sci, 2016; 12:1427–1436.
8.
MuikA, StubbertLJ, JahediRZ, et al.Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res, 2014; 74:3567–3578.
9.
ImmonenA, VapalahtiM, TyyneläK, et al.AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther, 2004; 10:967–972.
10.
KamranN, KadiyalaP, SaxenaM, et al.Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther, 2017; 25:232–248.
11.
NavaiN, BenedictWF, ZhangG, et al.Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon α2b formulated in Syn3 for failures of Bacillus Calmette–Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol, 2016; 23:4110–4114.
12.
Van LintS, RenmansD, BroosK, et al.The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines, 2015; 14:235–251.
13.
McNamaraMA, NairSK, HollEK. RNA-based vaccines in cancer immunotherapy. J Immunol Res, 2015; 2015:1–9.
14.
MeleroI, BermanDM, AznarMA, et al.Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 2015; 15:457–472.
15.
WangD, ZhangB, GaoH, et al.Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 2014; 14:251.
16.
RibasA. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther, 2005; 5:619–628.
17.
Argos Therapeutics. Independent data monitoring committee recommends discontinuation of the ADAPT Phase 3 clinical trial of Rocapuldencel-T in metastatic renal cell carcinoma for futility following its planned interim data review. ir.argostherapeutics.com/releasedetail.cfm?ReleaseID=1013884 (last accessed July14, 2017).
18.
BeckB, GeigerC, MunkerD, et al.Improving efficacy of dendritic cell vaccination in AML: optimization of the DC generation protocol and maximization of T cell responses by immune checkpoint blockade. Blood, 2013; 122:3492.
19.
Novartis. FDA briefing document: oncologic drugs advisory committee meeting. BLA 125646 Tisagenlecleucel. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf (last accessed July14, 2017).
20.
BerdienB, MockU, AtanackovicD, et al.TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther, 2014; 21:539–548.
21.
CastilloA. Gene editing using CRISPR-Cas9 for the treatment of lung cancer. Colomb Med (Cali), 2016; 47:178–180.
22.
ReardonS.First CRISPR clinical trial gets green light from US panel. Nature, 2016. DOI:10.1038/nature.2016.20137.
23.
RamamoorthM, NarvekarA. Non viral vectors in gene therapy- an overview. J Clin Diagn Res, 2015; 9:GE01-GE06.
24.
KohlhappFJ, KaufmanHL. Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res, 2016; 22:1048–1054.
25.
Food and Drug Administration. Highlights of prescribing information. www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf (last accessed July14, 2017).
26.
UngerechtsG, BossowS, LeuchsB, et al.Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev, 2016; 3:16018.
27.
HavunenR, SiuralaM, SorsaS, et al.Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol Ther oncolytics, 2017; 4:77–86.
28.
Bofill-De RosX, Rovira-RigauM, FillatC. Implications of microRNAs in oncolytic virotherapy. Front Oncol, 2017; 7:142.
29.
MarinoN, IllingworthS, KodialbailP, et al.Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. UlasovI, ed. PLoS One, 2017; 12:e0177810.
TriozziPL, AllenKO, CarlisleRR, et al.Cancer therapy: clinical Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res, 2005; 11:4168–4175.
34.
KantoffPW, HiganoCS, ShoreND, et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010; 363:411–422.
35.
Immatics. Immatics announces results of IMPRINT Phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC. immatics.com/immatics-announces-results-of-imprint-phase-3-clinical-trial-investigating-the-addition-of-ima901-to-standard-first-line-therapy-with-sunitinib-for-advancedmetastatic-rcc/ (last accessed July14, 2017).
36.
CureVac. CureVac provides clinical update at 35th Annual J.P. Morgan Healthcare Conference. www.curevac.com/news/curevac-provides-clinical-update-at-35th-annual-jp-morgan-healthcare-conference/ (last accessed July14, 2017).
37.
OttPA, HuZ, KeskinDB, et al.An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017; 547:217–221.
38.
SahinU, DerhovanessianE, MillerM, et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017; 547:222–226.
39.
DeFrancescoL. The “anti-hype” vaccine. Nat Biotechnol, 2017; 35:193–197.
40.
WilgenhofS, Van NuffelAMT, BenteynD, et al.A Phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol, 2013; 24:2686–2693.
41.
Van LintS, RenmansD, BroosK, et al.Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res, 2016; 4:146–156.
